Literature DB >> 34306459

Clinical efficacy of glucocorticoid and terbutaline in the treatment of acute exacerbation of chronic obstructive pulmonary disease.

Yan Li1,2, Zhi Xu1,2, Cuo Qing1,2, Hong Zhang1,2, Xia Wu1,2, Jilu Yang1,2.   

Abstract

BACKGROUND: To investigate the efficacy of glucocorticoid and terbutaline in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
METHODS: 248 patients with AECOPD were assigned into two groups, 124 patients in the control group were only given terbutaline treatment, while 124 patients in the experimental group were treated with glucocorticoid and terbutaline. The effect on lung function and blood gas indexes were compared between the two groups.
RESULTS: The total effective rate of the treatment with glucocorticoid and terbutaline was higher than that of control group (P < 0.05). After treatment, the pulmonary function indexes such as FEV1, FVC and PaO2 levels in the two groups were significantly higher than those before treatment, PaCO2 levels were significantly lower than that before the treatment (P < 0.05).
CONCLUSIONS: The combined use of glucocorticoid and terbutaline could effectively improve the lung function and blood gas indexes. It's of great significance to promote the rehabilitation of patients with AECOPD, and it provides insights for future clinical practice. AJTR
Copyright © 2021.

Entities:  

Keywords:  Glucocorticoid; acute exacerbation of chronic obstructive pulmonary disease; clinical efficacy; terbutaline

Year:  2021        PMID: 34306459      PMCID: PMC8290811     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  20 in total

1.  Is chronic obstructive pulmonary disease a risk factor for death in patients with community acquired pneumonia?

Authors:  Barbara Bonnesen; Gertrud Baunbæk Egelund; Andreas Vestergaard Jensen; Stine Andersen; Pelle Trier Petersen; Gernot Rohde; Pernille Ravn
Journal:  Infect Dis (Lond)       Date:  2019-04-02

2.  Acute Exacerbation According to GOLD 2017 Categories in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Joohae Kim; Chang-Hoon Lee; Myung-Goo Lee; Kyeong-Cheol Shin; Kwang Ha Yoo; Seong Yong Lim; Ju Ock Na; Chul-Gyu Yoo; Ki Suck Jung; Sang-Do Lee
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2019-03-25       Impact factor: 4.872

3.  The London Chest Activity of Daily Living scale cut-off point to discriminate functional status in patients with chronic obstructive pulmonary disease.

Authors:  Aline Almeida Gulart; Anelise Bauer Munari; Suelen Roberta Klein; Raysa Silva Venâncio; Hellen Fontão Alexandre; Anamaria Fleig Mayer
Journal:  Braz J Phys Ther       Date:  2019-03-26       Impact factor: 3.377

4.  Classification of Chronic Obstructive Pulmonary Disease (COPD) according to the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: Comparison with GOLD 2011.

Authors:  Raquel Marçôa; Daniela Marta Rodrigues; Margarida Dias; Inês Ladeira; Ana Paula Vaz; Ricardo Lima; Miguel Guimarães
Journal:  COPD       Date:  2017-11-21       Impact factor: 2.409

Review 5.  Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.

Authors:  Paolo Solidoro; Filippo Patrucco; Diego Bagnasco
Journal:  Expert Rev Respir Med       Date:  2019-09-13       Impact factor: 3.772

Review 6.  Imaging Advances in Chronic Obstructive Pulmonary Disease. Insights from the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene) Study.

Authors:  Surya P Bhatt; George R Washko; Eric A Hoffman; John D Newell; Sandeep Bodduluri; Alejandro A Diaz; Craig J Galban; Edwin K Silverman; Raúl San José Estépar; David A Lynch
Journal:  Am J Respir Crit Care Med       Date:  2019-02-01       Impact factor: 21.405

7.  Comparison of the efficacy of aerosol inhalation between the ipratropium bromide and terbutaline on the patients with AECOPD.

Authors:  Weiguo Xu; Junhua Wu; Yong Feng; Jing Zhu; Rong Cui
Journal:  Pak J Pharm Sci       Date:  2019-09       Impact factor: 0.684

8.  Serum bilirubin level is associated with exercise capacity and quality of life in chronic obstructive pulmonary disease.

Authors:  Ah Young Leem; Young Sam Kim; Ji-Hyun Lee; Tae-Hyung Kim; Ha Yan Kim; Yeon Mok Oh; Sang Do Lee; Ji Ye Jung
Journal:  Respir Res       Date:  2019-12-09

9.  The Severity of Oxidative Stress in Comorbid Chronic Obstructive Pulmonary Disease (COPD) and Hypertension: Does it Depend On ACE and AGT Gene Polymorphisms?

Authors:  Mariya Marushchak; Khrystyna Maksiv; Inna Krynytska; Olha Dutchak; Nina Behosh
Journal:  J Med Life       Date:  2019 Oct-Dec

10.  Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Authors:  Claus F Vogelmeier; Gerard J Criner; Fernando J Martinez; Antonio Anzueto; Peter J Barnes; Jean Bourbeau; Bartolome R Celli; Rongchang Chen; Marc Decramer; Leonardo M Fabbri; Peter Frith; David M G Halpin; M Victorina López Varela; Masaharu Nishimura; Nicolas Roche; Roberto Rodriguez-Roisin; Don D Sin; Dave Singh; Robert Stockley; Jørgen Vestbo; Jadwiga A Wedzicha; Alvar Agusti
Journal:  Respirology       Date:  2017-03-07       Impact factor: 6.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.